Patents Examined by Li Lee
-
Patent number: 9044436Abstract: The invention generally relates to compositions and methods of treatment and/or prevention of angiogenesis-related eye diseases using low doses of rhodostomin variants, and in particular, low doses of a fusion protein comprising a rhodostomin variant, wherein the rhodostomin variant is conjugated with a variant of Human Serum Albumin (HSA) where the cysteine residue at position 34 of the HSA amino acid sequence has been replaced with serine.Type: GrantFiled: December 22, 2010Date of Patent: June 2, 2015Assignees: National Cheng Kung University, National Taiwan UniversityInventors: Woei-Jer Chuang, Wen-Mei Fu, Yen-Lun Huang
-
Patent number: 8987198Abstract: Disclosed are methods of modulating the expression of genes linked to adipocytokine signaling, carbohydrate metabolism, fatty acid metabolism, arachidonic acid metabolism, PPAR signaling, insulin signaling, lipid metabolism, extracellular matrix (ECM)-receptor interaction, or combinations thereof, methods of treating hyperlipidemia, obesity, excessive cholesterol, cardiovascular disease, liver disease, diabetes, or combinations thereof, and methods of stimulating glucose uptake in an animal in need thereof, comprising administering a composition comprising at least one isolated glyceollin to said animal.Type: GrantFiled: December 22, 2010Date of Patent: March 24, 2015Assignees: The Administrators of the Tulane Educational Fund, The United States Department of Agriculture, Wake Forest University Health Sciences, Nume Health, LLCInventors: Matthew E. Burow, Stephen M. Boue, Thomas T. Y. Wang, Deepak Bhatnagar, Charles E. Wood, Mark L. Helman
-
Treatment of acute ischemic stroke or intracranial bleeding with tPa and carbamylated erythropoietin
Patent number: 8987190Abstract: The present invention relates a method for the treatment of intracranial bleeding comprising administration of a therapeutically effective amount of tPa and a therapeutically effective amount of carbamylated erythropoietin.Type: GrantFiled: November 15, 2010Date of Patent: March 24, 2015Assignee: H. Lundbeck A/SInventors: Thomas Nikolaj Sager, Michael Chopp, Zheng Gang Zhang -
Patent number: 8933031Abstract: Provided is a low molecular polypeptide that can inhibit angiogenesis consisting of amino acid sequence YRGKKA, which is same to one portion sequence in apolipoprotein (a) Kringle V. Also provided are pharmaceutical composition and the uses for preventing or treating diseases relating to angiogenesis.Type: GrantFiled: February 4, 2008Date of Patent: January 13, 2015Assignee: Shanghai First People's HospitalInventors: Hui Zhao, Xun Xu
-
Patent number: 8921305Abstract: Disclosed is a method for treating cancer and/or pain using an intra-patient dose escalation procedure to deliver dosages of crotoxin.Type: GrantFiled: January 22, 2013Date of Patent: December 30, 2014Assignee: Celtic Biotech Iowa, Inc.Inventor: Paul F. Reid
-
Patent number: 8912136Abstract: Disclosed are compositions and methods related to clot-binding compounds. For example, disclosed are compositions comprising a surface molecule and at least one modified clot-binding compound. The modified clot-binding compound can selectively bind to clotted plasma protein, wherein the composition causes clotting and amplifies the accumulation of the composition in tumors. The modified clot-binding compound can enhance the clotting in tumors compared to its unmodified derivative. The disclosed targeting is useful for treatment of cancer and other diseases and disorders.Type: GrantFiled: December 20, 2010Date of Patent: December 16, 2014Assignee: Sanford-Burnham Medical Research InstituteInventors: Erkki Ruoslahti, Lilach Agemy, Venkata Ramana Kotamraju
-
Patent number: 8895694Abstract: The invention relates to protracted Glucagon-Like Peptide-1 (GLP-1) derivatives and therapeutic uses thereof. The GLP-1 derivative of the invention comprises a modified GLP-1(7-37) sequence having a total of 2-12 amino acid modifications, including Glu22 and Arg26, and being derivatised with an albumin binding residue or pegylated in position 18, 20, 23, 30, 31, 34, 36, 37, or 39. These compounds are useful in the treatment or prevention of diabetes type 2 and related diseases. The compounds are potent, stable, have long half-lives, a high affinity of binding to albumin, and/or a high affinity of binding to the extracellular domain of the GLP-1 receptor (GLP-1R), all of which is of potential relevance for the overall aim of achieving long-acting, stable and active GLP-1 derivatives with a potential for once weekly administration.Type: GrantFiled: September 5, 2008Date of Patent: November 25, 2014Assignee: Novo Nordisk A/SInventors: Jane Spetzler, Lauge Schäffer, Jesper Lau, Thomas Kruse, Patrick William Garibay, Steffen Reedtz-Runge, Henning Thøgersen, Ingrid Pettersson
-
Patent number: 8883963Abstract: The present invention provides novel peptidomimetics, of formula (I), which primarily act as glucose dependent insulin secretagogues. Furthermore, it was found that these peptidomimetics showed glucagon receptor antagonistic activity, along with the GLP-I receptor agonistic activity.Type: GrantFiled: December 10, 2008Date of Patent: November 11, 2014Assignee: Cadila Healthcare LimitedInventors: Rajesh H. Bahekar, Mukul R. Jain, Pankaj Ramanbhai Patel
-
Patent number: 8871716Abstract: Disclosed are novel antimicrobial peptides which can promote the regeneration of skin cells, thus healing wounds. Pharmaceutical compositions comprising the peptides as active ingredients are also provided for wound healing and skin rejuvenation. The antimicrobial peptides exhibit inhibitory activity against antibiotic-resistant strains, and their antimicrobial activity is maintained without loss of structural stability even under a high salt condition. Also, being proven to promote the migration and regeneration of skin cells in mice as well as in vitro, the antimicrobial peptides may be widely used as an agent for regenerating skin cells. Further, they can find applications in various fields including the medical industry and the cosmetic industry. Hence, the novel antimicrobial peptides are anticipated to have considerable repercussions in the market for antibiotics, wound healing agents and cosmetics.Type: GrantFiled: April 27, 2011Date of Patent: October 28, 2014Assignees: Korea Advanced Institute of Science and Technology, Intelligent Synthetic Biology CenterInventors: Sun-Chang Kim, Da-Jung Kim, Su-A Jang, Bong Hyun Sung, Ki-Jung Lim, Ju-Ri Shin, Young Woong Lee
-
Patent number: 8835375Abstract: The invention relates to analogs of angiotensins, in particular to cyclised analogs having Ang(1-8) agonistic or antagonistic activity and to cyclised Ang(1-7) analogs with agonistic or antagonistic activity and displaying improved proteolytic resistance compared to their linear counterparts. Provided is a cyclic angiotensin peptide analog comprising a thioether-bridge linkage between the amino acids corresponding to positions Tyr4 and Pro7 in naturally occurring Angiotensin. Also provided is the use of analogs in therapy, for example hypertension.Type: GrantFiled: August 7, 2007Date of Patent: September 16, 2014Assignee: Applied Nanosystems B.V.Inventors: Marijke Haas, Leonardus Dorothea Kluskens, Anneke Kuipers, Rick Rink, Sieger Adriaan Nelemans, Gert Nikolaas Moll
-
Patent number: 8815797Abstract: The present invention relates in general to a shelf-stable liquid enteral composition for providing nutrition, either as a supplement, or as a complete nutrition, with a high protein content of a non-hydrolysed globular protein, in particular a whey protein.Type: GrantFiled: March 12, 2009Date of Patent: August 26, 2014Assignee: N.V. NutriciaInventors: Marcel Minor, Koenraad Gerard Christoffel Weel, Natalie Elizabeth Hotrum
-
Patent number: 8809263Abstract: The invention provides a method for preventing or treating a disease caused by an extracellular microorganism, said method comprising systemically administering to a subject in need thereof a prophylactically or therapeutically effective amount of a salicylic acid (SAL) or a SAL analogue. The extracellular microorganism can be of the bacterial genus Staphylococcus, for example, Staphylococcus aureus. The extracellular microorganism can be a strain that is resistant to at least one antibiotic. The strain can be selected from the group consisting of methycillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA).Type: GrantFiled: October 26, 2009Date of Patent: August 19, 2014Assignee: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical CenterInventors: Michael Yeaman, Arnold Bayer
-
Patent number: 8809262Abstract: The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3.Type: GrantFiled: April 21, 2009Date of Patent: August 19, 2014Assignees: Singapore Health Service Pte Ltd., Agency for Science, Technology and ResearchInventors: Roger W. Beuerman, Shouping Liu, Jing Li, Lei Zhou, Chandra Shekhar Verma, Donald Tan
-
Patent number: 8785386Abstract: The present invention provides a benzazepine compound that can maintain for a long period of time the blood level of tolvaptan enabling to provide the desired pharmaceutical effects. The benzazepine compound of the present invention is represented by general formula (1) wherein R1 represents a —CO—(CH2)n—COR2 group (wherein n is an integer of 1 to 4, and R2 is (2-1) a hydroxy group; (2-2) a lower alkoxy group optionally substituted with a hydroxy group, a lower alkanoyl group, a lower alkanoyloxy group, a lower alkoxycarbonyloxy group, a cycloalkyloxycarbonyloxy group, or 5-methyl-2-oxo-1,3-dioxol-4-yl; or (2-3) an amino group optionally substituted with a hydroxy-lower alkyl group), or the like.Type: GrantFiled: September 24, 2013Date of Patent: July 22, 2014Assignee: Otsuka Pharmaceutical Co., Ltd.Inventors: Kazumi Kondo, Yasuhiro Menjo, Takahiro Tomoyasu, Shin Miyamura, Yuso Tomohira, Takakuni Matsuda, Keigo Yamada, Yusuke Kato
-
Patent number: 8785374Abstract: The present invention provides novel peptides that inhibit and/or reduce the opening of mammalian tight junctions, i.e. peptide tight junction antagonists. The present invention also provides methods for the treatment of excessive or undesirable permeability of a tissue by administering to a subject suffering from such a condition a composition comprising a peptide tight junction antagonist of the invention.Type: GrantFiled: October 20, 2008Date of Patent: July 22, 2014Assignee: Alba Therapeutics CorporationInventor: Amir Tamiz
-
Patent number: 8759482Abstract: The invention provides methods for identifying and optimizing peptide substrates for enzymes such as lipoic acid ligase (Lp1A).Type: GrantFiled: October 19, 2010Date of Patent: June 24, 2014Assignee: Massachusetts Institute of TechnologyInventors: Alice Y. Ting, Sujiet Puthenveetil
-
Patent number: 8754035Abstract: The present invention relates generally to the field of cancer diagnosis and treatment, and more particularly to compositions and methods that may be useful for eliminating cancer cells with stem-like characteristics. The disclosed compositions and methods may also be useful for managing breast cancer, ovarian cancer, cervical cancer or endometrial (uterine) cancer with metastases; and visualizing the cancer cells in patient's body. The compositions of the instant invention include human prolactin receptor antagonist G129R.Type: GrantFiled: February 16, 2010Date of Patent: June 17, 2014Assignee: Oncolix, Inc.Inventor: Wen Y. Chen
-
Patent number: 8754039Abstract: This invention provides novel targeted antimicrobial compositions. In various embodiments chimeric moieties are provided comprising an antimicrobial peptide attached to a peptide targeting moiety that binds a bacterial strain or species.Type: GrantFiled: January 6, 2010Date of Patent: June 17, 2014Assignee: C3 Jian, Inc.Inventors: Randal H. Eckert, Chris Kaplan, Jian He, Daniel K. Yarbrough, Maxwell Anderson, Jee-Hyun Sim
-
Patent number: 8735343Abstract: Disclosed are compositions and methods for decreasing the viscosity and/or cohesiveness of and/or increasing the liquefaction of excessively or abnormally viscous or cohesive mucus or sputum. The composition contains a protein or peptide containing a thioredoxin active-site in reduced state and optionally further contains a reducing system.Type: GrantFiled: October 3, 2012Date of Patent: May 27, 2014Assignee: National Jewish HealthInventor: Carl W. White
-
Patent number: 8697629Abstract: A method of treating a disease characterized by aberrant cell migration and/or invasion includes administering to a subject an effective amount of the peptide of SEQ ID NO:3, an ?6 polypeptide, or an isolated polypeptide consisting essentially of the Link region of human CD44 as indicated in FIG. 17 to modulate a FAK signal transduction pathway for a sufficient period of time to treat the disease. A method of diagnosing a condition characterized by aberrant cell migration and/or invasion includes measuring the effect of these polypeptides on FAK signal transduction activity; wherein a change in FAK signal transduction activity is indicative of said aberrant cell migration or invasion. A method of diagnosing a condition characterized by aberrant cell migration and/or invasion includes imaging FAK signal transduction activity in the presence of these polypeptides.Type: GrantFiled: March 4, 2011Date of Patent: April 15, 2014Assignee: Angstrom Pharmaceuticals, Inc.Inventors: Malcolm Finlayson, Bassam B. Damaj